Pillar Biosciences Secures U.S. Nationwide Medicare Coverage for oncoReveal® CDx Pan-Cancer NGS Kit

 Pillar Biosciences, Inc., the leader in Decision Medicine™,  announced they have received nationwide Medicare coverage by the Centers fo...

April 04, 2025 | Friday | News
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from China’s NMPA for Melanoma Treatment

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...

April 02, 2025 | Wednesday | News
CHMP Recommends Opdivo® for EU Approval as Neoadjuvant and Adjuvant Treatment for Resectable NSCLC

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a...

March 31, 2025 | Monday | News
Novartis Announces FDA Approval for Expanded Use of Pluvicto® in mCRPC, Tripling Eligible Patient Access

Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with pro...

March 31, 2025 | Monday | News
China Grants Breakthrough Therapy Designation to Innovent’s IBI363 for Hard-to-Treat Melanoma

Innovent Biologics, Inc.  a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the trea...

March 31, 2025 | Monday | News
FDA Approves CABOMETYX® for Treatment of Advanced Neuroendocrine Tumors in Adults and Pediatric Patients

 Exelixis, Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the tre...

March 28, 2025 | Friday | News
Merck Reports Positive Phase 3 Results for Subcutaneous Pembrolizumab in Metastatic NSCLC

Merck known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the ...

March 28, 2025 | Friday | News
Candel Therapeutics Reports Promising Survival Data for CAN-2409 in Stage III/IV NSCLC Patients Resistant to ICI Treatment

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight ca...

March 27, 2025 | Thursday | News
Junshi Biosciences' Toripalimab (LOQTORZI®) Approved in Singapore for First-Line Treatment of Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

March 27, 2025 | Thursday | News
New Data at ELCC 2025 Reinforces Tagrisso's Role in Treating EGFR-Mutated Lung Cancer Across Stages

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso...

March 26, 2025 | Wednesday | Reports
CG Oncology Reports 75.5% Complete Response Rate in Phase 3 Bladder Cancer Study

CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-...

March 25, 2025 | Tuesday | Reports
Actinium Pharma Signs Actinium-225 Supply Deal with Eckert & Ziegler

Actinium Pharmaceuticals, Inc.(Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it has entered into an agreemen...

March 25, 2025 | Tuesday | News
CStone Pharmaceuticals Submits EMA Application for Sugemalimab to Treat Unresectable Stage III NSCLC

CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variati...

March 24, 2025 | Monday | News
Shanghai Junshi Biosciences' Toripalimab Receives NMPA Approval for First-Line Treatment of Metastatic Liver Cancer

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

March 24, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close